Neil Dahiya

Sunshine Biopharma Unveils Ursodiol for Treating Cholestatic Liver Conditions Including PBC

Sunshine Biopharma Inc., a company dedicated to developing and providing lifesaving pharmaceuticals in fields such as cancer and antiviral treatments, announced that its fully owned subsidiary, Nora Pharma Inc., based in Canada, has rolled out a generic prescription medication. The […]

Sunshine Biopharma Unveils Ursodiol for Treating Cholestatic Liver Conditions Including PBC Read More »

NIHR and OLS Invest in 7 Research Initiatives to Introduce New Technologies to NHS for Patient Advancement

The National Institute for Health and Care Research (NIHR) along with the Office for Life Sciences (OLS) have allocated funds to seven innovative research endeavors that are set to integrate new technologies into the NHS to benefit patients. Health innovation

NIHR and OLS Invest in 7 Research Initiatives to Introduce New Technologies to NHS for Patient Advancement Read More »

Chinese NMPA Reviews Akeso’s sNDA for Penpulimab Combined Therapy as a First-Line Treatment for Hepatocellular Carcinoma

Akeso, Inc., a prominent biopharmaceutical entity, has shared that the China National Medical Products Administration (NMPA) has received its supplementary new drug application (sNDA). This involves penpulimab, a distinct PD-1 monoclonal antibody, used alongside anlotinib for the frontline (1L) management

Chinese NMPA Reviews Akeso’s sNDA for Penpulimab Combined Therapy as a First-Line Treatment for Hepatocellular Carcinoma Read More »

Bill & Melinda Gates Foundation Awards BioSurfaces $2.06 Million Grant for BSCC Device Advancement

BioSurfaces, committed to enhancing global lives, revealed their receipt of a $2.06 million grant from the Bill & Melinda Gates Foundation. This one-year funding is dedicated to advancing their Bio-Spun Cell Chamber (BSCC), a groundbreaking device aimed at delivering a

Bill & Melinda Gates Foundation Awards BioSurfaces $2.06 Million Grant for BSCC Device Advancement Read More »

J&J Requests FDA Approval for Tremfya’s Subcutaneous Induction Therapy in Ulcerative Colitis

Johnson & Johnson has revealed that it has filed a supplemental Biologics License Application (sBLA) with the US Food and Drug Administration (FDA), aiming for the endorsement of a subcutaneous (SC) induction treatment using Tremfya (guselkumab) for adults experiencing moderate

J&J Requests FDA Approval for Tremfya’s Subcutaneous Induction Therapy in Ulcerative Colitis Read More »

iiCON Backs Innovative Phase II Evaluation of PnuBioVax, a New Vaccine for Pneumococcal Disease

The Infection Innovation Consortium, known as iiCON, is overseeing a groundbreaking £3.2 million Medical Research Council-backed study, aimed at advancing the development of a new vaccine targeting pneumococcal disease. This illness, notorious for high antibiotic resistance, is a leading cause

iiCON Backs Innovative Phase II Evaluation of PnuBioVax, a New Vaccine for Pneumococcal Disease Read More »

KISMA Raises Alarms Over Fresh MSR, Seeks NCISM’s Exemption for Current Colleges from Guidelines

The Kerala-based Consortium of Self-Financing Ayurveda Institutions (KISMA) has voiced unease regarding the updated regulations set by the National Commission for Indian System of Medicine (NCISM). These revisions aim to oversee and standardize the essential criteria for academic institutions and

KISMA Raises Alarms Over Fresh MSR, Seeks NCISM’s Exemption for Current Colleges from Guidelines Read More »